The effect of bivalirudin on coagulation function in male patients with coronary heart disease undergoing...

Area of Science:

• Cardiology
• Pharmacology
• Hematology

Background:

• Coronary heart disease (CHD) poses a significant cardiovascular risk.
• Percutaneous coronary intervention (PCI) is a common revascularization procedure for CHD.
• Effective anticoagulation is crucial during PCI to prevent thrombotic events.

Purpose of the Study:

• To evaluate the effect of bivalirudin versus unfractionated heparin on coagulation function in male CHD patients undergoing PCI.
• To compare the incidence of major adverse cardiovascular events (MACCE), stent thrombosis, and bleeding between the two anticoagulant groups.

Main Methods:

• A randomized controlled trial involving 90 male CHD patients undergoing PCI.
• Patients were assigned to either bivalirudin or unfractionated heparin.
• Coagulation parameters (ACT, TT, PT, APTT, Fib, PLT) and clinical outcomes were assessed.

Main Results:

• No significant differences in coagulation parameters (ACT, TT, PT, APTT, Fib, PLT) were observed between groups at various time points.
• The bivalirudin group exhibited a lower incidence of stent thrombosis and bleeding within 24 hours post-PCI.
• No significant difference in MACCE was found between the groups after 13 months of follow-up.

Conclusions:

• Bivalirudin offers advantages over unfractionated heparin in PCI for CHD patients, including rapid onset, short half-life, and reduced early thrombosis and bleeding.
• While short-term benefits are evident, long-term MACCE rates were comparable between the two anticoagulants.